Affix Pharmaceuticals Profile
Key Indicators
- Authorised Capital ₹ 0.10 M
- Paid Up Capital ₹ 0.10 M
- Company Age 9 Year, 6 Months
- Last Filing with ROC 31 Mar 2023
- Revenue Growth 163.89%
- Profit Growth 148.89%
- Ebitda -52.19%
- Net Worth 24.11%
- Total Assets 80.42%
About Affix Pharmaceuticals
Affix Pharmaceuticals Private Limited (APPL) is a Private Limited Indian Non-Government Company incorporated in India on 18 August 2015 (Nine years and six months 10 days old ). Its registered office is in Delhi, India.
The Company is engaged in the Trading Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2023. It's a company limited by shares with an authorized capital of Rs 0.10 M and a paid-up capital of Rs 0.10 M, as per Ministry of Corporate Affairs (MCA) records.
The Key Managerial Personnel (KMP) at Affix Pharmaceuticals Private Limited India is Rajnish Singh as CEO. Garima Singh, Ritesh Singh, and Poonam Singh serve as directors at the Company.
Company Details
- Location
Delhi, India
- Telephone
+91-XXXXXXXXXX
- Email Address
- Website
-
- Social Media -
Corporate Identity Details
- CIN/LLPIN
U24230DL2015PTC284171
- Company No.
284171
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
18 Aug 2015
- Date of AGM
30 Sep 2023
- Date of Balance Sheet
31 Mar 2023
- Listing Status
Unlisted
- ROC Code
Roc Delhi
Industry
Who are the key members and board of directors at Affix Pharmaceuticals?
Executive Team (1)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
| Rajnish Singh | CEO | 07-Mar-2024 | Current |
Board Members (3)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Garima Singh  | Director | 10-Apr-2023 | Current |
| Ritesh Singh | Director | 02-Dec-2020 | Current |
| Poonam Singh | Director | 01-Sep-2023 | Current |
Financial Performance of Affix Pharmaceuticals.
Affix Pharmaceuticals Private Limited, for the financial year ended 2020, experienced significant growth in revenue, with a 163.89% increase. The company also saw a substantial improvement in profitability, with a 148.89% increase in profit. The company's net worth Soared by an impressive increase of 24.11%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metrics |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Affix Pharmaceuticals?
In 2017, Affix Pharmaceuticals had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Charges (Loans)
There are no open charges registered against the company as per our records.
How Many Employees Work at Affix Pharmaceuticals?
Unlock and access historical data on people associated with Affix Pharmaceuticals, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Affix Pharmaceuticals, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Affix Pharmaceuticals's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
